AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06352632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NoNO-42
Description: NoNO-42 at weight-based dosing - 2.6 mg/Kg, administered as a single IV infusion with a 20-minute dosing duration
Study NCT06352632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No deferoxamine mesylate and no colchicine
Description: No deferoxamine mesylate and no colchicine
Study NCT06352632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine mesylate only
Description: Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days
Study NCT06352632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine only
Description: 0.5mg of oral colchicine daily for 30 days
Study NCT06352632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Both deferoxamine mesylate and colchicine
Description: Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days
Study NCT06121492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acid
Description: In the BCAA group, participants will receive oral BCAA for 24 weeks, with a daily dosage of approximately 13.68 g/day. Each sachet of BCAA will contain 6.84 g of BCAA (valine 1.82 g, leucine 3.29 g, isoleucine 1.72 g), total protein 17.08 g, carbohydrates 25.48 g, fat 5.66 g, providing 221.2 kcal of energy. Each sachet weighs 52 g and should be mixed with 150 ml of water. Participants will consume 2 sachets daily, one after breakfast and one after dinner.
Study NCT06121492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.
Study NCT05613985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care alone
Description: Usual Care is defined as the following procedures to apply to the foot ulcer, carried out in the order in which they are listed:~Sharp debridement (the debridement will be performed only if non-vital tissue is present), Mild washing of the whole ulcer with physiological solution, Treatment with topical antiseptic containing Iodopovidone, Covering with iodopovidone impregnated gauze while the ulcer is clinically infected (PEDIS ≥ 2) \[If, during the study, PEDIS is \< 2, the ulcer will be covered with nonadherent paraffin gauze\].~Treatment 2 times a week (4 treatment weeks, 8 treatments).
Study NCT05613985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care
Description: System VULNOFAST® plus / VULNOLIGHT®: VULNOFAST® plus sterile solution, in combination with a red light source VULNOLIGHT®. VULNOFAST® plus and VULNOLIGHT® will be used in accordance with their Instructions for Use (IFU) and User Manual.~Treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®).
Study NCT05774704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low curcumin group
Description: One curcumin capsule (250 mg curcumin) after each meal, 3 times a day for 2 weeks.
Study NCT05774704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High curcumin group
Description: One curcumin capsule (500 mg curcumin) after each meal, 3 times a day for 2 weeks.
Study NCT05869123 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Online adaptive radiotherapy
Description: PTV with 5 margins covers CTV
Study NCT05376124 — intervention group
Intervention type: OTHER
Intervention: original therapy
Description: * Patients on ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②Patients who received TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③Patients who received TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
Study NCT05376124 — intervention group
Intervention type: OTHER
Intervention: rescue therapy
Description: TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
Study NCT06636539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEM Exam in Investigational Device
Description: All subjects enrolled in this study will undergo a CEM exam using Investigational Device.
Study NCT06517225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual-acoustic biofeedback
Description: Behavioral: Visual-acoustic biofeedback In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. The web-based software staRt will be used for intervention delivery.
Study NCT06517225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual-acoustic biofeedback
Description: Behavioral: Visual-acoustic biofeedback In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. The web-based software staRt will be used for intervention delivery.
Study NCT05742516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bimuno Daily
Description: Galactooligosaccharide supplement within Bimuno Daily
Study NCT05742516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin powder
Study NCT05332743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol Vegan Women's Hair Supplement
Description: Nutrafol's Vegan Women's Hair Supplement with patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, Curcumin, Saw Palmetto, 20% Tocotrienol/Tocopherol complex, and capsaicin in combination with other vegan nutrients used to support hair health such as Pea Sprout Extract, Bamboo, and a new innovative Maldavian Dragonhead flower extract.
Study NCT05951075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Power Prenatal for Sperm
Description: A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm
Study NCT06438016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Training
Description: The intervention will comprise of 4 sessions delivered over 4 weeks. The training session will be structured as follows: Session 1 - Psychoeducation relating to stress and its effects. Session 2 - Behavioral techniques to cope with stress 1, Session 3 - Cognitive techniques to cope with stress and Session 4- Behavioral techniques to cope with stress. Both verbal and written means will be used to provide this training.
Study NCT05818956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-227
Description: TAK-227 capsules.
Study NCT02802423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLEX 404 Oral Liquid
Description: BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
Study NCT06359041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CABA-201
Description: Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Study NCT05917496 — intervention group
Intervention type: OTHER
Intervention: LENA tool: Language ENvironment Analysis
Description: Recording of the language environment of the child at home, in daily environment, with the LENA.~The parameters recorded relate to four domains: adult words, conversation turns, child vocalizations and exposure to electronic media.~The LENA box is worn for 10-16 hours, with a minimum of 10 consecutive hours. the families make 2 separate recordings of 6 months at T1 and T2.
Study NCT05917496 — intervention group
Intervention type: BEHAVIORAL
Intervention: Return of the analysis of the data of LENA
Description: The analysis of the LENA data is carried out by the speech therapist using the LENA Pro Version Software v3.4, during the times T1 and T2. The return of the analysis of the data collected via the LENA will be made to the family of the patient after T1 and after T2 and personalized advice will then be given to parents with the aim of improving their child's language skills.
Study NCT06167291 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm 1- Ipsilateral
Description: Given by I-RT
Study NCT05098574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yaz
Description: Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
Study NCT05098574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appearance, packaging, and labeling of placebo will be matched to their active counterpart.
Study NCT06220201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-97540
Description: Specified dose on specified days
Study NCT06220201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days
Study NCT05455697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT05455697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05455697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT05455697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT05455697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Given IV
Study NCT05455697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC
Study NCT05455697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV
Study NCT05455697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given vincristine
Study NCT05455697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT05455697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05455697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET/CT
Study NCT05455697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET
Study NCT05455697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG-CT
Study NCT05455697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05455697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV
Study NCT06182475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPPComm Provider Training
Description: A curriculum will be developed to educate patients about LDKT and promote the search of potential living donors while supporting patients' values and cultural preferences. The curriculum will consist of two components: didactic education and skills-based communication. The didactic component provides evidence of the impact of patient-provider communication and LDKT process outcomes for Black and Caucasian patients. The skills-based component will build communication confidence leading discussions about LDKT. It provides instructions for the key communication skills needed to confidently assuage patients' concerns about LDKT/live donation and motivates patients to search for living donor. The following will be covered: providing LDKT information/answering questions, highlighting LDKT benefits, refuting live donation misinformation, and encouraging patients to seek living donors.
Study NCT06777758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol dose reduction ratio
Study NCT06777758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol dose reduction ratio
Study NCT06220201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study NCT06294613 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: vitreoretinal surgery
Description: Patients undergoing vitreoretinal surgery
Study NCT05463341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fentanyl Test Strips
Description: A brief fentanyl test strip (FTS) education intervention will be given to participants at Project DAWN sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
Study NCT04109638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endonovo SofPulse
Description: The active device emits PEMF signal whereas the placebo device does not emit a PEMF signal. The active device is on for 15 minutes at a time, every two hours, for 10 days.
Study NCT05716113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD13-02 cell infusion
Description: CAR-T cells
Study NCT04109638 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Endonovo SofPulse
Description: The active device emits PEMF signal whereas the placebo device does not emit a PEMF signal. The active device is on for 15 minutes at a time, every two hours, for 10 days.
Study NCT06193343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Daily Step Promotion
Description: Participants will wear a Fitbit monitor on their non-dominant wrist during a 10 to 14 day run-in screening to capture daily steps reported by the Fitbit but no daily step goals will be sent to the participant. The Fitbit monitor will be worn during all waking hours except water activities, and compliance will be considered as a day with ≥1,000 steps. Next, participants will undergo a 16-week intervention wearing the Fitbit monitor on their wrist and receive a text message each morning with a personalized, adaptive daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day. Goals will not exceed 10,000 daily steps.
Study NCT05106049 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum Adiponectin
Description: serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.
Study NCT06532851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise (PRE)
Description: A structured exercise regimen focusing on increasing muscular strength and endurance through progressive resistance.
Study NCT06532851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: An exercise program focusing on cardiovascular conditioning using a stationary bike.
Study NCT06532851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A set of general strength and balance exercises that do not target the specific therapeutic goals of the other interventions.
Study NCT05529277 — intervention group
Intervention type: OTHER
Intervention: Dementia Care Management
Description: Comprehensive assessment of health care needs of person with cognitive impairment and caregiver followed by algorithm-/ and person-based support in health care planning, implementing and monitoring
Study NCT05362942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax, Decitabine, Azacytidine, Cytarabine
Description: Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days (n=3) or azacytidine (n=8) was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician. Cytarabine was given at a dose of 10 mg/m2 twice daily for 7 days.
Study NCT05936840 — intervention group
Intervention type: DEVICE
Intervention: Mira Monitor tracking
Description: Using the Mira monitor to track the menstrual cycle
Study NCT05254990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: Reparixin 600 mg tablets, administered orally at the dose of 1200 mg TID (2 tablets TID) as add-on therapy to standard of care up to 21 days. IMP can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that reparixin is taken with food. However, if the patient is unable to eat, the study drug may still be administered without concomitant food ingestion.
Study NCT05254990 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally three times a day (TID) as add-on therapy to standard of care up to 21 days.~Placebo can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that placebo is taken with food. However, if the patient is unable to eat, the placebo may still be administered without concomitant food ingestion.
Study NCT06311773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boomerang Catheter
Description: The study device used for this procedure makes an anastomosis between a tibial vein and a tibial artery to direct blood flow around blocked arteries.
Study NCT06631287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4mg encapsulated, pre-formed tablet PO once daily for 24 weeks.
Study NCT06631287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated, pre-formed tablet PO once daily for 24 weeks.
Study NCT04585477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVENIO ctDNA Surveillance Kit
Description: Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
Study NCT04585477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AVENIO ctDNA Surveillance Kit
Description: Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
Study NCT04585477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants in the intervention arm will receive Durvalumab (1500 mg IV every 4 weeks for up to 12 months) as monotherapy or 20mg/kg if weight is 30kg or less.
Study NCT05739279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: STAR-Sonographic Thigh Adjustment Ratio
Description: With ultrasonography, anterior thigh muscle thickness on the dominant extremity side will be measured at a 50% level between the anterior superior iliac spine and the upper pole of the patella in the supine position. The STAR-sonographic thigh adjustment ratio will be calculated by dividing the anterior thigh muscle thickness (mm) by the body mass index.
Study NCT05739279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hand Grip Strength
Description: Hand grip strength will be measured with a Jamar dynamometer used in the second grip position, in a sitting position with shoulders adducted and neutrally rotated, elbows flexed to 90°, and forearms/wrists in the neutral position. Three repetitive measurements will be made from the dominant side and the maximum value obtained for analysis will be taken.
Study NCT04585477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
Description: Participants in the intervention arm (Cohort 1 MRD+) will receive a fixed dose of Durvalumab (1500 mg IV every 4 weeks for up to 12 months), either as monotherapy or in combination with a platinum-based chemotherapy regimen (investigator's choice). Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.